A Director at Vericel Corp is Exercising Options


Today it was reported that a Director at Vericel Corp (VCEL), Robert Zerbe, exercised options to buy 17,500 VCEL shares at $2.63 a share, for a total transaction value of $46.03K.

This recent transaction increases Robert Zerbe’s holding in the company by 38888.89% to a total of $301.1K.

See today’s analyst top recommended stocks >>

Currently, Vericel Corp has an average volume of 348.1K. The Company has a Price to Book ratio of 7.8412.

Starting in March 2018, VCEL received 24 Buy ratings in a row. Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $21.10, reflecting a 23.5% upside. Five different firms, including Needham and Ladenburg, currently also have a Buy rating on the stock.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies to repair and regenerate damaged tissues and organs to normal structure and function. Its product portfolio include MACI and Epicel.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts